4 November 2025
EMA/352482/2025
Committee for Veterinary Medicinal Products (CVMP)

Committee for Veterinary Medicinal Products

Minutes of the 7-9 October 2025 meeting

Note on access to documents

Some documents mentioned in the minutes cannot be released at present within the framework of Regulation (EC) No 1049/2001 on access to documents because they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/729522/2016).

The meeting was held in person.

i. Adoption of the Agenda

The Committee adopted the agenda with one additional topic under section 13. AOB.

ii. Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CVMP plenary session 7-9 October 2025

The attendance list was completed and competing interests were identified for the October 2025 meeting. In accordance with the Agency's policy and procedure on the handling of competing interests, participants in this meeting were asked to declare any interests on the matters discussed (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting took place in full respect of the restricted involvement of CVMP members and, where relevant, experts attending the plenary meeting, as announced by the CVMP secretariat at the start of the meeting (see Annex I). All decisions taken at this meeting were made in presence of a quorum of members i.e. 17 or more members of the 32 members eligible to vote were present. Furthermore, absolute majority requires that 17 members vote in favour of the proposed decision.

iii. Declaration of contacts between members and companies with regard to points on the agenda

Information relating to declared contacts between members and companies with regard to points on the agenda cannot be released at the present time as it is deemed to be commercially confidential.

No contacts have been declared

iv. Adoption of the minutes of the previous meeting

The minutes of the June, July, and September 2025 meetings were adopted with no amendments.

v. Topics for rapporteur's meetings, break-out sessions held in advance or in the margins of the present CVMP meeting

Information relating to briefing meetings taking place with applicants/marketing authorisation holders cannot be released at the present time as it is deemed to be commercially confidential.

1. Maximum residue limits

1.1. Opinions

No items

1.2. Oral explanations

No items

1.3. List of outstanding issues

No items

1.4. List of questions

No items

1.5. Re-examination of CVMP opinions on maximum residue limits

No items

1.6. Other issues

No items

2. Marketing authorisations

2.1. Opinions

2.1.1. EMEA/V/C/006455/0000 – dogs

Indication: for the reduction of pain associated with osteoarthritis (OA) in dogs.

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion, the CVMP assessment report and the product information.

The Norwegian member agreed with the above-mentioned recommendations.

Action: For information

The Committee noted the summary of opinion. The CVMP also noted two peer review reports and the comments from two CVMP members.

2.1.2. Vaxxitek HVT+IBD+H5 – Avian influenza vaccine (live recombinant) - EMEA/V/C/006751/0000 – chickens, turkeys

Indication: intended for:

- active immunisation of one-day-old chicks or 18-day-old embryonated chicken eggs to reduce mortality, clinical signs and virus excretion due to infection with highly pathogenic avian influenza virus (HPAI) virus of the H5 subtype, including the circulating clade 2.3.4.4b.
- active immunisation of one-day-old turkeys to reduce mortality, clinical signs and virus excretion due to infection with HPAI virus of the H5 subtype, including the circulating clade 2.3.4.4b.

Exceptional circumstances

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion, the CVMP assessment report and the product information.

The Norwegian member agreed with the above-mentioned recommendations.

Action: For information

The Committee noted the summary of opinion. The CVMP noted two peer review reports and the comments from four CVMP members.

2.2. Oral explanations

2.2.1. EMEA/V/C/006535/0000 - dogs

Action: Oral explanation held on 7 October 2025.

The Committee listened to an oral explanation from the applicant and noted the rapporteur's assessment of the responses to list of outstanding issues.

2.3. List of outstanding issues

No items

2.4. List of questions

2.4.1. EMEA/V/C/006804/0000 – cattle

Action: For adoption

The Committee adopted the scientific overview and list of questions together with the comments on the product information.

The Committee noted two peer review reports and comments from two CVMP members.

2.5. Re-examinations of CVMP opinions

No items

2.6. Other issues

2.6.1. EMEA/V/C/006645/0000 – chickens

Action: For decision

The Committee agreed to the request from the applicant for an extension of the clock stop.

3. Variations to marketing authorisations

3.1. Opinions

3.1.1. YURVAC RHD – rabbit haemorrhagic disease and RHDV2 vaccine (recombinant) - EMA/VRA/0000294120 – rabbits

Variation requiring assessment: to implement the outcome of the MAH's signal management process to add transient anorexia and intestinal stasis as very rare adverse events.

Rapporteur: R. Carapeto García

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion and the product information.

The Norwegian member agreed with the above-mentioned recommendations.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

3.1.2 Vectormune HVT-AIV – avian influenza vaccine (live recombinant) - EMA/VRA/0000288171 – chickens

Variation requiring assessment: to submit additional in-use stability data, to solve the first of three specific obligations identified during the initial marketing authorisation.

Rapporteur: C. Miras

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion, the CVMP assessment report and the product information.

The Norwegian member agreed with the above-mentioned recommendations.

3.2. Oral explanations

No items

3.3. List of outstanding issues

3.3.1. Dexdomitor – dexmedetomidine - EMA/VRA/0000257740 – dogs, cats

Variation requiring assessment: change(s) to therapeutic indication(s) - addition of a new therapeutic indication or modification of an approved one.

Rapporteur: H. Bremer, Co-Rapporteur: M. Leppänen

Action: For decision

The Committee decided that an oral explanation was not needed.

Action: For adoption

The Committee adopted the list of outstanding issues and the comments on the product information.

3.4. List of questions

3.4.1. Startvac – *Staphylococcus aureus* and coagulase-negative staphylococci and *Escherichia coli* J5 vaccine (inactivated) - EMA/VRA/0000288186 – cattle

Variation requiring assessment: efficacy-related change.

Rapporteur: E. Werner, Co-Rapporteur: C. Muñoz Madero

Action: For adoption

The Committee adopted the list of questions and the comments on the product information.

3.5. Re-examinations of CVMP opinions on variations requiring assessment

No items

3.6. Other issues

No items

4. Referrals and related procedures

4.1. Union interest referral under Article 82 of Regulation (EU) 2019/6

No items

4.2. Union interest referral under Article 82 based on Article 129(3) of Regulation (EU) 2019/6

No items

4.3. Procedure under Article 70(11) of Regulation (EU) 2019/6 due to lack of consensus between Member States in the SPC harmonisation procedure

No items

4.4. Request for clarification from the European Commission under Article 54(8) of Regulation (EU) 2019/6 on a CMDv review procedure

4.4.1. Variation procedure for Phenoxypen WSP – phenoxymethylpenicillin potassium – EMA/REF/0000302825

Scope: Efficacy

Step: Start of procedure

Action: For decision

The Committee considered the request for clarification from the European Commission for Phenoxypen WSP, 325 mg/g powder for oral solution use in drinking water for pigs and chickens due to a lack of consensus between Member States in the CMDv review procedure on a variation requiring assessment. The Committee agreed to start a procedure under Article 54(8) of Regulation (EU) 2019/6 and appointed A. Golombiewski as rapporteur and K. Boerkamp as co-rapporteur, and two CVMP members, as peer reviewers for the procedure. The Committee adopted the list of questions and the timetable for the procedure.

4.5. Request from the European Commission under Article 130(4) of Regulation (EU) 2019/6 on suspending, revoking or varying the terms of centrally authorised products

No items

4.6. Request for a scientific opinion/advice under Articles 141(1)(c), 141(1)(e) or 141(1)(i) of Regulation (EU) 2019/6

4.6.1. Veterinary medicinal products containing amoxicillin (as a single active substance) in pigs for use in drinking water or in feed, for respiratory indications – EMA/REF/0000290626

The topic was postponed to the November 2025 meeting of the Committee.

4.7. Other issues

Information on certain topics discussed under section 4.7 cannot be released at the present time as it is deemed to be confidential

No items

5. Post-authorisation issues for marketing authorisations

Information relating to GMP, pharmacovigilance inspections, supervision and sanctions will not be published as it would undermine the purpose of such inspections.

5.1. Pharmacovigilance

5.1.1. Coxevac – *Coxiella burnetii* vaccine (inactivated)

Rapporteur: C. Miras, Co-Rapporteur: C. Muñoz Madero

Action: For adoption

The Committee adopted the outcome of the signal management process.

5.2. Post-authorisation measures

No items

5.3. Inspections and controls

No items

5.4. Re-examination of limited markets and exceptional circumstances authorisations

No items

5.5. Others

No items

6. Working parties

Information relating to certain topics discussed under section 6 cannot be released at the present time as it is deemed to be commercially confidential.

6.1. Antimicrobials Working Party (AWP)

6.1.1. Verbal report on AWP meeting held on 23-24 September 2025

Action: For information

The Committee received a verbal report on the AWP meeting held on 23-24 September 2025 and noted its agenda together with the minutes of the meeting held on 27-28 May 2025.

6.1.2. Concept paper for the development of a guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in companion animal species

Action: For discussion

The Committee discussed the concept paper for the development of a guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in companion animal species. Adoption of the document is expected for the November meeting of the Committee.

6.2. Environmental Risk Assessment Working Party (ERAWP)

6.2.1. Upcoming election of the Vice-chair

Action: For information

The Committee was informed of the upcoming election for the vice-chair position following the resignation of B. Kolar as of 1 October 2025. A call for nominations will be launched after the meeting.

6.3. Efficacy Working Party (EWP-V)

No items

6.4. Immunologicals Working Party (IWP)

No items

6.5. 3Rs Working Party (3RsWP)

6.5.1. Verbal report on 3RsWP meeting held on 18-19 September 2025

Action: For information

The Committee received a verbal report on the 3RsWP meeting held on 18-19 September 2025 and noted its agenda together with the minutes of the 20-21 May 2025 meeting.

6.6. Novel Therapies & Technologies Working Party (NTWP)

6.6.1. Verbal report on NTWP meeting held on 18 September 2025

Action: For information

The Committee received a verbal report on the NTWP meeting held on 18 September 2025 and noted its agenda

6.7. Pharmacovigilance Working Party (PhVWP-V)

6.7.1. Verbal report on PhVWP-V meeting held on 23-24 September 2025

Action: For information

The Committee received a verbal report on the PhVWP-V meeting held on 23-24 September 2025 and noted its agenda together with the draft summary record of the September 2025 PhVWP-V meeting. The Committee also noted the draft PhVWP-V Work Plan 2026 and the final summary record of the July 2025 PhVWP-V meeting.

6.7.2. Revised VeDDRA call for comments

Action: For adoption

The Committee adopted the revised VeDDRA call for comments.

6.8. Quality Working Party (QWP)

6.8.1. Verbal report on QWP meetings (July-September 2025)

Action: For information

The Committee received a verbal report on the July and September 2025 QWP meetings.

The minutes of the QWP meeting held on 11-12 June 2025, the agenda and minutes of the QWP meeting held on 14-15 July 2025 together with the agenda of the QWP meeting held on 8-9 September 2025 were noted.

6.8.2. Questions and answers on skip testing

Action: For adoption

The Committee adopted the Q&As on skip testing to be published on Quality of medicines questions and answers: Part 2.

6.9. Scientific Advice Working Party (SAWP-V)

6.9.1. Verbal report on SAWP-V meeting held on 3 October 2025

Action: For information

The Committee received a verbal report on the SAWP-V meeting held on 3 October 2025 and noted its agenda together with the final minutes meeting held on 5 September 2025.

6.10. Safety Working Party (SWP-V)

6.10.1. Appointment of a new SWP-V member

Action: For decision

The Committee appointed Malene Nissen as the new SWP-V member.

6.11. Other working party and scientific group issues

No items

7. Other scientific matters

Information on scientific matters or other critical issues cannot be released at the present time as it is deemed to be confidential

7.1. MRL issues

No items

7.2. Environmental risk assessment

No items

7.3. Antimicrobial resistance

7.3.1. Appointment of temporary Working Party experts on Dosage Review and Adjustment of established Antibiotics (ADRA)

Action: For decision

The Committee appointed the experts of ADRA tWP namely: i) PK/PD modelling on antibiotics - Alexis Viel, Aranzazu Gonzalez-Canga, Damien Bouchard, Viviane Filor; ii) Efficacy of antibiotics and Target animal safety (TAS) - Lucie Pokludova, Raul Belmar Liberato, Viviane Filor; iii) Withdrawal periods/withdrawal period modelling - Jesus Alberto Sanchez Rodriguez, Walid Oumessad; iv) Environmental risk assessment (ERA) - Irene de la Casa Resino, Kathi Westphal-Settele.

7.3.2. Work plan for the Dosage Review and Adjustment of established Antibiotics (ADRA) temporary Working Party 2025-2026

Action: For adoption

The Committee adopted the work plan for the ADRA temporary Working Party 2025-2026.

7.3.3. Appointment of temporary Working Party Chair on Dosage Review and Adjustment of established Antibiotics (ADRA)

Action: For information

The Committee noted the call for nominations for Chair of the CVMP temporary Working Party (tWP) on ADRA, including the selection procedure and draft timetable.

7.4. Pharmacovigilance

No items

7.5. Vaccine antigen master file (VAMF) certification

Information on this section cannot be released at the present time as it is deemed to be commercially confidential.

No items

7.6. Platform technology master file (PTMF) certification

Information on this section cannot be released at the present time as it is deemed to be commercially confidential.

7.6.1 EMEA/V/VPTMF/0004

Action: For adoption

The Committee adopted the vPTMF assessment report including the LoOI.

7.7. Other issues

8. Co-operation with other EU or International bodies

Information on certain topics discussed under section 8 cannot be released at the present time as it is deemed to be commercially confidential.

8.1. VICH

8.2. Codex Alimentarius

No items

8.3. Other EU bodies and international organisations

9. Procedural and regulatory matters

Information relating to limited markets classifications, new applications and eligibility requests for Union marketing authorisations and certain regulatory matters cannot be released at the present time as it is deemed to be commercially confidential.

9.1. Limited markets classifications according to Article 4(29) and confirmation of eligibility for authorisation according to Article 23 of Regulation (EU) 2019/6

9.1.1. Request for classification

Action: For classification

The Committee discussed the CVMP recommendation for veterinary medicinal product for honeybees as intended for a limited market and not eligible for authorisation under Article 23 of Regulation (EU) 2019/6.

9.1.2. Draft Questions and answers on classification of a product as intended for a limited market according to Article 4(29) and/or eligibility for authorisation according to Article 23 (Applications for limited markets)

Action: For discussion

The Committee discussed the questions and answers on classification of a product as intended for a limited market according to Article 4(29) and/or eligibility for authorisation according to Article 23 (Applications for limited markets).The document identifies the areas that are not covered in the Guidance to Applicants (GtA) and adds further explanations for applicants on limited markets and article 23 Adoption of the document is expected for the November meeting of the Committee.

9.2. Eligibility for centralised procedures, appointment of rapporteurs, co-rapporteurs and peer reviewers

9.3. Regulatory matters

10. Organisational and strategic matters

10.1. Appointment of co-opted members

Action: For election

The Committee elected, by majority, Mary O'Grady as the co-opted member for Quality (Chemicals).

The Committee elected, by majority, Rory Breathnach as the co-opted member for General Clinical Veterinary Practice.

10.2. Verbal report on Veterinary Domain meeting held on 16 September 2025

Action: For information

The Committee received a verbal report on Veterinary Domain (VetD) meeting held on 16 September 2025 and noted its agenda together with the minutes of the 23 May 2025 meeting.

10.3. CVMP work plan 2026

Action: For discussion

The Committee discussed the CVMP work plan 2026.

10.4 Code of conduct of the European Medicines Agency – provisions for members and experts of scientific committees

Action: For information

The Committee received a verbal report on the updated Code of conduct of the European Medicines Agency (link).

11. CMDv

11.1. Verbal report from Chair of CMDv on the CMDv plenary meeting held on 17-18 September 2025

Action: For information

The Committee received a verbal report from the Chair of CMDv on the CMDv plenary meeting held on 17-18 September 2025 and noted its agenda.

12. Legislation

No items

13. Any other business

13.2. Meeting highlights

Action: For comments

Meeting highlights (link)

14. Annex

2. Marketing authorisations and extensions

2.6. Other issues under Regulation (EC) No 726/2004

EMEA/V/C/006593 – horses

Action: For information

The Committee noted the letter of withdrawal of the marketing authorisation application for Equidormin. A WEPAR will be published on EMA's website in due course.

3. Variations to marketing authorisations

3.1. Opinions

Porcilis Porcoli Diluvac Forte – *E. coli* vaccine (inactivated) – EMA/VRA/0000269151 – pigs

Variation requiring assessment: to align the product information with version 9.1 of the QRD template.

Rapporteur: J. Poot

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion and the product information.

The Norwegian CVMP member agreed with the above-mentioned recommendations.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Respiporc FLUpan H1N1, Respiporc Flu 3 – Porcine influenza vaccine (inactivated) – EMA/VRA/0000258482 – pigs

Variation requiring assessment: quality-related changes.

Rapporteur: M. Blixenkrone-Møller

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

The Norwegian CVMP member agreed with the above-mentioned recommendation.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Emdocam – meloxicam – EMA/VRA/0000269297 – horses

Variation requiring assessment: to align the product information with version 9.1 of the QRD template.

Rapporteur: P. McNeill

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion and the product information.

The Norwegian CVMP member agreed with the above-mentioned recommendations.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Posatex / Mometamax Ultra - EMA/VRA/0000285701 - dogs

Variation requiring assessment: quality-related changes.

Rapporteur: S. Louet

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

The Norwegian CVMP member agreed with the above-mentioned recommendation.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

3.4. List of questions

Cirbloc M Hyo – Porcine circovirus and porcine enzootic pneumonia vaccine (inactivated) - EMA/VRA/0000288333 – pigs

Variation requiring assessment: quality-related changes.

Rapporteur: K. Baptiste

Action: For adoption

The Committee adopted the list of questions.

Eluracat – capromorelin tartrate - EMA/VRA/0000288081 – cats

Variation requiring assessment: quality-related changes.

Rapporteur: R. Carapeto

Action: For adoption

The Committee adopted the list of questions.

Mirataz – mirtazapine - EMA/VRA/0000288548 – cats

Variation requiring assessment: to align the product information with version 9.1 of the QRD template.

Rapporteur: S. Louet

Action: For adoption

The Committee adopted the list of questions and the comments on the product information .

Senvelgo – velagliflozin – EMA/VRA/0000293237 – cats

Variation requiring assessment: quality-related changes

Rapporteur: K. Baptiste

Action: For adoption

The Committee adopted the rapporteur's assessment report including list of questions.

Nobivac L4, Canigen L4, Nobivac LoVo L4 – EMA/VRA/0000284846 – dogs

Variation requiring assessment: quality-related changes.

Rapporteur: E. Dewaele

Action: For adoption

The Committee adopted the rapporteur's assessment report including list of questions.

4. Referrals and related procedures

4.6. Request for a scientific opinion/advice under Articles 141(1)(c), 141(1)(e) or 141(1)(i) of Regulation (EU) 2019/6

Quarter-based selective dry cow therapy – EMA/REF/0000285673

Scope: Antimicrobial resistance

Rapporteur: A. Golombiewski, Co-Rapporteur: M. Leppänen

Action: For decision

The Committee agreed to the request from Animal Health Europe for an extension of the period for public consultation.

Action: For adoption

The Committee adopted the revised timetable.

4.7. Other issues

5. Post-authorisation issues for marketing authorisations

5.1 Pharmacovigilance

Signal evaluation and recommendations

Action: For adoption

The Committee adopted the monthly outcomes of the signal management process (October 2025) and the list of finalised signals.

5.2 Post-authorisation measures

Purevax RCPCh FeLV – EMA/PAM/0000287615

Post-authorisation recommendation

Rapporteur: E. Dewaele

Action: For endorsement

The Committee endorsed the rapporteur's assessment report on the data submitted in responses to the Committee's recommendation which is now considered fulfilled.

DuOtic – EMA/PAM/0000287416

Post-authorisation recommendation

Rapporteur: P. McNeill

Action: For endorsement

The Committee endorsed the rapporteur's assessment report on the data submitted in responses to the Committee's recommendation which is now considered fulfilled.

5.3 Inspections and controls under Regulation (EU) 2019/6

6. Working parties

6.8 Quality Working Party (QWP)

Quality Chemical ESEC nominations

Action: For adoption

The Committee adopted the list of nominations for the Quality Chemical ESEC.

7. Other scientific matters

7.7. Other issues

8. Co-operation with other EU or International bodies

8.1. VICH

9. Procedural and regulatory matters

9.1. Limited markets classifications according to Article 4(29) and confirmation of eligibility for authorisation according to Article 23 of Regulation (EU) 2019/6

9.3. Regulatory matters

Invented names

ANNEX I

List of participants including any restrictions with respect to involvement of members/alternates/ experts following evaluation of declared interests for the 7-9 October 2025 CVMP meeting, which was held in person.

An asterisk (*) after the role, in the first column, signals that the participant attended remotely.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics for which restriction apply
G. Johan Schefferlie	**Chair**	**CHAIR**	**No interests declared**	
Petra Falb	Member	Austria	No restrictions applicable to this meeting	
Manuela Leitner*	Alternate	Austria	No interests declared	
Els Dewaele	Member	Belgium	No interests declared	
Krasimir Zlatkov	Member	Bulgaria	No interests declared	
Leona Nepejchalová	Member	Czechia	No interests declared	
Merete Blixenkrone-Møller	Alternate	Denmark	No interests declared	
Toomas Tiirats	Member	Estonia	No restrictions applicable to this meeting	
Minna Leppänen	Member	Finland	No interests declared	
Kristina Lehmann*	Alternate	Finland	No interests declared	
Sylvie Louet*	Member	France	No interests declared	
Christine Miras	Alternate	France	No interests declared	
Esther Werner*	Alternate	Germany	No interests declared	
Spyridon Farlopoulos	Member	Greece	No interests declared	
Gábor Kulcsár	Member	Hungary	No participation in discussion, final deliberations and voting on:	EMEA/V/C/006751/0000 EMA/VRA/0000293237 EMA/PAM/0000287615
Paul McNeill	Member	Ireland	No interests declared	
Alice Blennerhassett*	Alternate	Ireland	No interests declared	
Fulvio Marsilio	Member	Italy	No interests declared	
Renate Kuske*	Alternate	Latvia	No restrictions applicable to this meeting	
Vaida Kurapkiene*	Alternate	Lithuania	No restrictions applicable to this meeting	
Despoina Iatridou*	Alternate	Luxembourg	No interests declared	
Caroline Coner	Member	Luxembourg	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics for which restriction apply
Kim Boerkamp	Alternate	Netherlands	No restrictions applicable to this meeting	
Hanne Bergendahl	Member	Norway	No interests declared	
Knud Sveen Torjesen*	Alternate	Norway	No interests declared	
Ewa Augustynowicz	Alternate	Poland	No interests declared	
Marcin Glanda*	Alternate	Poland	No interests declared	
João Pedro Duarte Da Silva*	Member	Portugal	No interests declared	
Gabriela Tuchila	Member	Romania	No interests declared	
Eva Chobotová	Member	Slovakia	No interests declared	
Urska Peunik	Alternate	Slovenia	No interests declared	
Cristina Muñoz Madero*	Member	Spain	No interests declared	
Frida Hasslung Wikström	Member (Vice-Chair)	Sweden	No interests declared	
Hanna Bremer	Alternate	Sweden	No interests declared	
Ricardo Carapeto García	Co-opted member	Spain	No interests declared	
Rory Breathnach	Co-opted member	Ireland	No restrictions applicable to this meeting	
Mary O'Grady	Co-opted member	Ireland	No interests declared	
Carina Bergman	Co-opted member	Sweden	No interests declared	

An asterisk (*) after the role, in the first column, signals that the participant attended in person.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics on agenda for which restrictions apply
Renata Kovacova	Expert	Slovakia	No interests declared	
Ayla Hesp	Expert	Netherlands	No interests declared	
Elisabeth Begon	Expert	France	No interests declared	
Frida Martin	Expert	Sweden	No interests declared	
Jonathan Bergman	Expert	Sweden	No restrictions applicable to this meeting	
Fredrik Hulten	Expert	Sweden	No interests declared	
Helena Back	Expert	Sweden	No interests declared	
Kathrin Dietze	Expert	Germany	No interests declared	
Nuria Doñamayor Alonso	Expert	Germany	No restrictions applicable to this meeting	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics on agenda for which restrictions apply
Christina Bredtmann	Expert	Germany	No interests declared	
Laura Kulisch	Expert	Germany	No interests declared	
Andrea Springer	Expert	Germany	No interests declared	
Khadija Selouaoui	Expert	France	No interests declared	
Martine Redureau	Expert	France	No interests declared	
Pascale Macours	Expert	France	No interests declared	
Mahrez Zerrouki	Expert	France	No interests declared	
Anne Sagnier	Expert	France	No interests declared	
Sarah Buckley	Expert	Ireland	No interests declared	
Gavin Ryan	Expert	Ireland	No interests declared	
Emily Hams	Expert	Ireland	No interests declared	
Lorena Touriño González	Expert	Spain	No interests declared	
Anne Malene Nissen	Expert	Denmark	No interests declared	
Kathrine Just Andersen	Expert	Denmark	No interests declared	
Kirsten Brolin Thomsen	Expert	Denmark	No interests declared	
Marta Martin Juarez	Expert	Spain	No interests declared	
Alberto de Prado Lopez	Expert	Spain	No interests declared	
Adrián Fandiño López	Expert	Spain	No interests declared	
Maria Ferrer	Expert	Spain	No interests declared	
Carlos Ballesteros	Expert	Spain	No interests declared	
Rosario Bullido	Expert	Spain	No interests declared	
Aranzazu González-Canga	Expert	Spain	No interests declared	
Sonia Gil Morales	Expert	Spain	No interests declared	
Luis Agote Casado	Expert	Spain	No interests declared	
Christian Kühne	Expert	Germany	No interests declared	
Cristina Ballesteros Tercero	Expert	Spain	No interests declared	
Jaime García Sanchez	Expert	Spain	No restrictions applicable to this meeting	
Monika Hofmann	Expert	Germany	No interests declared	
Rolf Beckmann	Expert	Germany	No interests declared	
Jana Hundt	Expert	Germany	No interests declared	
Dagmar Sommer	Expert	Germany	No interests declared	
Daniela Loos	Expert	Germany	No interests declared	
Babett Kobe	Expert	Germany	No interests declared	
Heike Gyra	Expert	Germany	No interests declared	
Sandra-Maria Wienhold	Expert	Germany	No restrictions applicable to this meeting	

CVMP working parties and CMDv	Chair
AWP	Damien Bouchard*
IWP	Esther Werner*
QWP	Marie-Hélène Sabinotto *(veterinary vice chair)**
SAWP-V	Frida Hasslung Wikström
SWP-V	Carina Bergman
EWP	Cristina Muñoz Madero*
3Rs	Sarah Adler-Flindt *(vet vice-chair)**
QWP	Marie-Helene Sabinotto*
PhVWP-V	James Mount*
Observers from SwissMedic (Switzerland) attended the meeting	
A representative from the European Commission attended the meeting	
Meeting run with support from the relevant EMA staff.	

Experts' declared interests were evaluated against the agenda topics or activities they participated in.